China SXT Pharmaceuticals, Inc. (SXTC)
NASDAQ: SXTC · IEX Real-Time Price · USD
1.240
+0.100 (8.77%)
Jul 26, 2024, 4:00 PM EDT - Market closed
China SXT Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Year Ending | TTM | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | 2017 - 2015 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.7 | 1.97 | 2.6 | 4.78 | 5.16 | 7.01 | Upgrade
|
| Revenue Growth (YoY) | -38.81% | -24.23% | -45.53% | -7.45% | -26.38% | -0.10% | Upgrade
|
| Cost of Revenue | 1.08 | 1.55 | 1.35 | 1.94 | 2.46 | 2.4 | Upgrade
|
| Gross Profit | 0.62 | 0.43 | 1.25 | 2.84 | 2.7 | 4.61 | Upgrade
|
| Selling, General & Admin | 14.08 | 5.68 | 6.44 | 5.04 | 4.04 | 2.84 | Upgrade
|
| Operating Expenses | 14.08 | 5.68 | 6.44 | 5.04 | 4.04 | 2.84 | Upgrade
|
| Operating Income | -13.46 | -5.26 | -5.19 | -2.2 | -1.34 | 1.77 | Upgrade
|
| Interest Expense | -0.43 | -0.48 | -0.04 | -1.12 | -3.35 | -0.01 | Upgrade
|
| Interest & Investment Income | - | - | 0 | 0.01 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0.1 | 0.15 | -0.18 | 0.36 | -0.07 | 0.03 | Upgrade
|
| EBT Excluding Unusual Items | -13.79 | -5.59 | -5.41 | -2.94 | -4.76 | 1.79 | Upgrade
|
| Asset Writedown | -0.35 | -0.35 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | -5.63 | - | Upgrade
|
| Pretax Income | -14.14 | -5.93 | -5.41 | -2.94 | -10.39 | 1.79 | Upgrade
|
| Income Tax Expense | - | - | 0.33 | -0.19 | -0.1 | 0.25 | Upgrade
|
| Net Income | -14.14 | -5.93 | -5.74 | -2.75 | -10.29 | 1.54 | Upgrade
|
| Net Income to Common | -14.14 | -5.93 | -5.74 | -2.75 | -10.29 | 1.54 | Upgrade
|
| Net Income Growth | - | - | - | - | - | 29.61% | Upgrade
|
| Shares Outstanding (Basic) | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 504.34% | 541.90% | 44.50% | 132.79% | 20.23% | - | Upgrade
|
| EPS (Basic) | -30.30 | -22.23 | -137.92 | -95.48 | -832.08 | 149.67 | Upgrade
|
| EPS (Diluted) | -30.30 | -22.23 | -137.92 | -95.48 | -832.08 | 149.67 | Upgrade
|
| Free Cash Flow | -0.16 | -0.15 | 0.21 | -1.41 | 0.53 | -0.36 | Upgrade
|
| Free Cash Flow Per Share | -0.35 | -0.57 | 4.95 | -48.98 | 42.67 | -34.97 | Upgrade
|
| Gross Margin | 36.70% | 21.62% | 48.10% | 59.43% | 52.37% | 65.77% | Upgrade
|
| Operating Margin | -790.19% | -266.68% | -199.43% | -45.99% | -25.98% | 25.24% | Upgrade
|
| Profit Margin | - | - | -220.43% | -57.52% | -199.29% | 21.95% | Upgrade
|
| Free Cash Flow Margin | -9.50% | -7.68% | 7.91% | -29.50% | 10.22% | -5.13% | Upgrade
|
| EBITDA | -13.21 | -5.01 | -4.87 | -1.85 | -1.01 | 1.95 | Upgrade
|
| EBITDA Margin | - | -253.99% | -187.13% | -38.76% | -19.55% | 27.82% | Upgrade
|
| D&A For EBITDA | 0.24 | 0.25 | 0.32 | 0.35 | 0.33 | 0.18 | Upgrade
|
| EBIT | -13.46 | -5.26 | -5.19 | -2.2 | -1.34 | 1.77 | Upgrade
|
| EBIT Margin | - | -266.68% | -199.43% | -45.99% | -25.98% | 25.24% | Upgrade
|
| Effective Tax Rate | - | - | - | - | - | 14.08% | Upgrade
|
| Revenue as Reported | 1.7 | 1.97 | 2.6 | 4.78 | 5.16 | 7.01 | Upgrade
|
Source: S&P Capital IQ. Standard template.